China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...

If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...

Grogan served as assistant to President Trump and director of the Domestic Policy Council 2019-2020. On April 15, President Trump issued an awaited executive order on drug pricing, kicking off a new ...

The confluence of China’s rapidly rising biotech prowess and US policy decisions that hamper the industry is a cause for ...

Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New ...

T he biotech and pharmaceutical sectors stand at the brink of innovation and strategic transformation. Market momentum continues to build, with the global biotechnology market valued at around $2 ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

To share your story, or find out how to get involved with CNBC Cures, email CNBC.cures@cnbc.com China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in ...

The Philippine pharmaceutical industry has attracted more than P18 billion in investments within Philippine Economic Zone ...